Rowena Gardner appointed to board at One Nucleus

Rowena Gardner has been appointed as a non-executive director at One Nucleus.

She will bring industry operations and communications expertise to the not-for-profit membership organisation, which champions the life sciences cluster in the East of England and London.

Rowena, who is VP operations and company secretary for Wellcome Genome Campus-based microbiome science company Microbiotica, recently left a role as communications consultant with MedImmune after six years, after the brand was absorbed into AstraZeneca.

Previous roles included chief operating officer at the UK BioIndustry Association (BIA) and director of corporate communications for Cambridge Antibody Technology Group. At CAT, Rowena oversaw integrated financial communications through a NASDAQ listing, refinancing, High Court litigation and M&A.

One Nucleus’ chief executive Tony Jones said: “Ro will be an excellent addition to the One Nucleus board. Not only bringing extensive knowledge of the needs of growing life science companies throughout their life cycle, Ro has true depth in understanding how we best harness and air the voice of our members to potential investors, partners and policy makers.

“We fully expect Ro to play a vital role as we continue the development of One Nucleus as the go to organisation for those seeking to engage with and support life sciences in our region.”

Rowena said: “Having been closely involved with One Nucleus for a number of years, I very much look forward to working with the team to support their future objectives.

“These are challenging times for the sector and One Nucleus is extremely well placed to connect and champion the cluster in order to catalyse business creation and growth. I am delighted to have been asked to join the board and look forward to bringing my experience to the table, to supporting the team and assisting One Nucleus members.”

Read more

How Microbiotica is getting closer to a blueprint of your body's bacteria

MedImmune brand retired as its work is integrated into AstraZeneca